Latest Conference Articles

Blood-based tumor mutational burden was hypothesized to be predictive of benefit on atezolizumab treatment in patients with non–small cell lung cancer, but a study has shown otherwise.

Jesús García-Foncillas, MD, PhD, discusses the rationale behind comparing the efficacy of larotrectinib and entrectinib head-to-head in patients with metastatic solid tumors with neurotrophic gene fusions.

Results from the MRTX-500 trial show that sitravatinib administered in combination with nivolumab can elicit durable response and lead to robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.

Exploratory results from the phase 3 IMpower010 trial look positive fo the use of adjuvant atezolizumab in various non–small cell lung cancer populations.

Among patients with malignant pheochromocytoma and paraganglioma, treatment with sunitinib demonstrated improved efficacy.

Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.

Data from the phase 1/2 KRYSTAL-1 study presented at the 2021 ESMO congress showed promising clinical activity with adagrasib in treating previously treated patients with KRASG12C-mutated colorectal cancer.

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

The combination of nivolumab/ipilimumab did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal cancer.

In patients with high-risk nonmetastatic prostate cancer treatment involving abiraterone acetate and prednisolone with or without enzalutamide added to androgen deprivation therapy for 2 years led to meaningfully enhanced survival outcomes.

In patients with metastatic castration resistant prostate cancer, sabizabulin was well tolerated and associated with significant and durable objective tumor responses

Clinically effective results in a group of patients with HRD-positive, chemotherapy-naïve metastatic castration resistant prostate cancer was induced with nivolumab plus rucaparib.

In the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, the combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone.

In patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations, datopotamab deruxtecan, an antibody drug conjugate, demonstrated safe antitumor activity.

Progression-free survival after [vic]-trastuzumab duocarmazine treatment in patients with pretreated, metastatic HER2-positive breast cancer was improved compared with physician’s choice chemotherapy.

According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Patients with previously treated HER2-positive metastatic breast cancer experienced a clinically meaningful and statistically significant improvement in progression-free survival with fam-trastuzumab deruxtecan-nxki vs standard of care trastuzumab emtansine in the DESTINY-Breast03 trial.

In patients with persistent, recurrent, or metastatic cervical cancer the addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates.

Compared with a placebo, adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death in patients with resected, high-risk stage II melanoma.

In previously untreated patients with metastatic or unresectable melanoma, the addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone.

Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.

In a presentation at the 2021 ESMO Congress, researchers discussed how nivolumab plus ipilimumab showed superior efficacy results after a 5-year follow-up in comparison to single-agent sunitinib.

An exploratory subgroup analysis of the CheckMate 9ER trial discussed at the 2021 ESMO Congress showed significant benefits to progression-free survival for patients with renal cell carcinoma on nivolumab and cabozantinib regardless if they had prior nephrectomy.

Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the efficacy of larotrectinib in patients with TRK-fusion cancers.

Cabozantinib is a feasible perioperative treatment and induced responses in patients with intermediate and poor-risk metastatic renal cell carcinoma.

In Western patients with HER2-positive gastric/gastroesophageal junction cancer Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate.

In patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression, the addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes.

Pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer were improved with The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide.